Rybelsus Faces 2.5-2.6% Price Cut in November under CEA Scheme; No Change for Cabometyx

Novo Nordisk Pharma’s oral GLP-1 agent Rybelsus (semaglutide) will see its NHI price trimmed by 2.5-2.6% under the cost-effectiveness assessment (CEA) system, with the reduction to be carried out on November 1. Rybelsus’ 3 mg, 7 mg, and 14 mg...read more